private label tobacco products Cigarettes: Building Your Brand with Eastern PRIVATE LABEL – FUMAR

Federal Not applicable under Federal law State None Federal See additional information and requirements on advertising, labeling and promotion requirements -- available here.

Symptomatic management includes: Antitussives (dextromethorphan) or expectorants (guaifenesin) for symptom relief Short-acting bronchodilator (albuterol) via nebulizer (CPT 94640) if wheeze or bronchospasm present Inhaled corticosteroid (ICS) short course may reduce cough duration in selected patients Antivirals (oseltamivir) for influenza-confirmed cases within 48 hours of onset Acute Bronchiolitis (Pediatric) Supportive care is the mainstay per AAP Clinical Practice Guideline: supplemental O (target SpO 90%), hydration, nasal suctioning

[20] 2021: "Commit to quit"

Failure to comply with the Tobacco 21 law will result in a misdemeanor